Detroit, MINCT03850366Now EnrollingIRB Ready

Hematological Malignancy Clinical Trial in Detroit, MI

Access cutting-edge hematological malignancy treatment through this clinical trial at a research site in Detroit. Study-provided care at no cost to qualified participants.

Sponsored by Henry Ford Health System

Quick Self-Assessment

See if you qualify for this Detroit location

Preparing your pre-screening questions…

Expert Care in Detroit

Access hematological malignancy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hematological malignancy treatment provided free

Apply for This Detroit Location

Check if you qualify for this hematological malignancy clinical trial in Detroit, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Detroit

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Detroit site if eligible
  4. 4Begin participation

About This Hematological Malignancy Study in Detroit

Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patients with hematologic malignancies who need allogeneic stem cell transplant but do not have a suitable matched related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and bortezomib

Sponsor: Henry Ford Health System

Who Can Participate

Inclusion Criteria

18-65 years old patient lacking a matched related donor or unrelated donor but have a related haploidentical donor (\</= 7/8 allele match at the A, B, C, DR loci with a minimum match of 5/10 is required) is identified
Candidate for stem cell transplant in a malignant hematological condition
Karnofsky Performance Scale 0-1
Available donor able to undergo a Peripheral blood stem cells collection
Bilirubin \</= 1.5 mg/dl , aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \</= 200 IU/ml for adults.
Serum creatinine clearance \>/=60 ml/min (calculated with Cockroft-Gault formula)
Diffusing capacity for carbon monoxide (DLCO) \>/= 45% predicted corrected for hemoglobin.
Left ventricle ejection fraction \> 40%.
Patient or patient's legal representative, parent(s) or guardian should provide written informed consent.

Exclusion Criteria

Adult who has a suitable related or unrelated donor or cord units available for transplant. Suitable donors include 8/8 (HLA-A,B,C and DR, with all loci high-resolution typing) or 7/8 related or unrelated donor available within 42 days of search initiation
HIV positive; active hepatitis B or C
Patients with active uncontrolled infections.
Liver cirrhosis
Uncontrolled central nervous system involvement by tumor cells
Positive Beta Human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
Inability to comply with medical therapy or follow-up

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT03850366) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematological Malignancy Treatment Options in Detroit, MI

If you're searching for hematological malignancy treatment options in Detroit, MI, this clinical trial (NCT03850366) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hematological malignancy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematological malignancy clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Detroit, MI

See all interstitial cystitis clinical trials recruiting in Detroit — not just this study.

Browse Interstitial Cystitis Trials in Detroit

Browse More Trials by Condition

Ready to Join in Detroit?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Detroit, MI